PMC:7346000 / 24978-25297 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"687","span":{"begin":59,"end":71},"obj":"Chemical"},{"id":"688","span":{"begin":76,"end":84},"obj":"Chemical"},{"id":"704","span":{"begin":169,"end":177},"obj":"Disease"}],"attributes":[{"id":"A688","pred":"tao:has_database_id","subj":"688","obj":"MESH:C000626907"},{"id":"A704","pred":"tao:has_database_id","subj":"704","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"New antifungal classes currently under development, namely fosmanogepix and olorofim [91], may have equal efficacy without the same burden of drug–drug interactions and toxicity, and may therefore overcome the limitations of currently available antifungals and become the preferred treatment options in the near future."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T177","span":{"begin":4,"end":14},"obj":"Chemical"},{"id":"T178","span":{"begin":142,"end":146},"obj":"Chemical"},{"id":"T179","span":{"begin":147,"end":151},"obj":"Chemical"},{"id":"T180","span":{"begin":245,"end":256},"obj":"Chemical"}],"attributes":[{"id":"A177","pred":"chebi_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A178","pred":"chebi_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A179","pred":"chebi_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A180","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"}],"text":"New antifungal classes currently under development, namely fosmanogepix and olorofim [91], may have equal efficacy without the same burden of drug–drug interactions and toxicity, and may therefore overcome the limitations of currently available antifungals and become the preferred treatment options in the near future."}

{"project":"LitCovid-sentences","denotations":[{"id":"T132","span":{"begin":0,"end":319},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"New antifungal classes currently under development, namely fosmanogepix and olorofim [91], may have equal efficacy without the same burden of drug–drug interactions and toxicity, and may therefore overcome the limitations of currently available antifungals and become the preferred treatment options in the near future."}

{"project":"2_test","denotations":[{"id":"32599813-31649174-60095158","span":{"begin":86,"end":88},"obj":"31649174"}],"text":"New antifungal classes currently under development, namely fosmanogepix and olorofim [91], may have equal efficacy without the same burden of drug–drug interactions and toxicity, and may therefore overcome the limitations of currently available antifungals and become the preferred treatment options in the near future."}